Table 1.
Patient, Donor, Disease and Transplant Characteristics
| Characteristics of patients | N (%) |
|---|---|
| Number of patients | 573 |
| Age, median (range), years | 56 (21–74) |
| ≥ 60 | 184 (32) |
| Sex Male | 428 (75) |
| Race / ethnicity | |
| Caucasian | 530 (92) |
| African-American | 25 ( 4) |
| Asian | 1 (<1) |
| Multiple | 2 (<1) |
| Unknown | 15 ( 3) |
| Karnofsky performance score | |
| <80% | 44 ( 8) |
| 80–100% | 492 (86) |
| Missing | 37 ( 6) |
| HCT-CI | |
| 0–2 | 273 (47) |
| 3+ | 63 (11) |
| Not Available | 237 (41) |
| Donor age, median (range), years | 33 (19–60) |
| Lines of prior chemotherapy | |
| ≤3 | 223 (39) |
| >3 | 35 ( 6) |
| Unknown / missing | 315 (55) |
| Disease status | |
| CR / PR / nPR | 193 (34) |
| Stable/Progressive / untreated | 372 (65) |
| Missing | 8 ( 1) |
| Time from diagnosis to transplant, median (range) months URD HLA match | 59 (1–323) |
| 8/8 | 466 (81) |
| 7/8 | 107 (19) |
| Graft source | |
| Bone marrow | 118 (21) |
| Peripheral blood | 455 (79) |
| Donor-recipient CMV status | |
| Recipient positive | 166(29) |
| Recipient negative / donor positive | 214 (37) |
| Recipient negative / donor negative | 161 (28) |
| Conditioning regimen intensity | |
| Myeloablative | 131 (23) |
| RIC / NMA | 438 (77) |
| Unknown | 4 (<1) |
| TBI in conditioning | 220 (38) |
| In vivo T cell depletion | |
| None | 356 (62) |
| Anti-thymocyte globulin | 150 (26) |
| Alemtuzumab | 67 (12) |
| GVHD prophylaxis | |
| Tac+ MMF ± other(s) | 141 (25) |
| Tac MTX ± other(s) and Tac ± other(s) | 251 (43) |
| CSA + MTX or MMF ± other(s) | 111 (19) |
| CSA ± other(s) | 64 (12) |
| Other(s) | 6 ( 1) |
| Year of transplant | |
| 1995–1999 | 29 ( 5) |
| 2000–2004 | 146 (25) |
| 2005–2009 | 299 (52) |
| 2010–2014 | 99 (17) |
| Recipient expressing HLA C1 | 467 (82) |
| Recipient expressing HLA C2 | 325 (57) |
| Recipient expressing HLABw4 | 331 (58) |
| Donor KIR Genotype | |
| KIR AA | 187 (33) |
| KIR Bx | 386 (67) |
| Donor with KIR2DS1 | 205 (36) |
| Donor with KIR3DL1 | 549 (96) |
Abbreviations: HCT-CI hematopoietic cell transplantation – comorbidity index, URD unrelated donor, ATG, antithymocyte globulin; CSA, cyclosporin A; CR, complete response; nPR, nodal partial response; PR, partial response; RIC reduced intensity conditioning, NMA non-myeloablative conditioning, TBI total body irradiation, MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus